FibroBiologics, Inc. Share Price & Technical Analysis
FBLG · $1.05 (0.00%)
Healthcare / Biotechnology
$1.05
0.00%
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCe…
Price chart
Seasonality
May has 1 positive and 2 negative years (last 3 years shown)
-23% return in May, -4% avg return in past 3 year May month.
-49% return in 2026, -170% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 38% | -1% | -80% | 18% | -23% | – | – | – | – | – | – | – | -49% |
| 25 | -19% | -21% | -30% | 12% | -35% | -17% | 2% | -7% | -8% | -28% | -28% | -18% | -196% |
| 24 | -3% | -60% | -22% | -13% | 27% | -59% | 8% | -69% | 90% | -3% | -14% | -25% | -143% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.27M
P/E ratio
—
52W high
$19.80
52W low
$0.95
Volume
65,989
Beta
1.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is FibroBiologics, Inc. share price today?
- FibroBiologics, Inc. (FBLG) last traded around $1.05 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does FBLG have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for FBLG. Download the app for real-time alerts.
- How can I analyze FibroBiologics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.